Galectin Therapeutics Inc. (GALT) is a publicly traded Healthcare sector company. As of May 21, 2026, GALT trades at $2.21 with a market cap of $144.23M and a P/E ratio of -4.51. GALT moved +6.25% today. Year to date, GALT is -43.04%; over the trailing twelve months it is +71.32%. Its 52-week range spans $0.73 to $7.13. Analyst consensus is buy with an average price target of $11.00. Rallies surfaces GALT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Belapectin trial cuts varices risk by up to 68%; cash runway to April 2027: Galectin Therapeutics reported a 2025 net loss of $31 million and ended the year with $17.7 million cash plus a $10 million credit line, extending runway to April 2027. NAVIGATE Phase 2b/3 data showed a 49.3% varices incidence reduction per protocol and 68.1% reduction in U.S. patients treated with belapectin 2 mg/kg versus placebo.
| Metric | Value |
|---|---|
| Price | $2.21 |
| Market Cap | $144.23M |
| P/E Ratio | -4.51 |
| EPS | $-0.48 |
| Dividend Yield | 0.00% |
| 52-Week High | $7.13 |
| 52-Week Low | $0.73 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-30.84M |
| Gross Margin | 0.00% |
1 analysts cover GALT: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $11.00.